data_2maa_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2maa _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.51 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.1 110.899 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 73.43 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 70.23 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.43 111.104 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 72.5 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 73.32 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.123 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 73.45 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.45 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 70.02 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 tp . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.12 111.151 -179.991 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.41 110.927 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.02 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 74.34 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.4 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.3 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 64.4 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 72.3 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 75.24 111.12 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.13 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 75.34 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.22 111.132 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 75.24 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 73.31 110.95 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.15 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 73.1 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 75.52 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 75.2 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 75.42 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.3 111.146 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 74.53 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 73.22 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 75.2 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.2 tp . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 72.44 111.144 -179.983 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.31 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 73.43 110.88 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.33 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 73.13 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.407 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.35 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 61.33 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.3 111.142 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 74.51 110.929 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.12 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.3 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 74.22 111.098 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.12 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.44 110.943 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.35 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 70.44 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.51 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 74.12 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.1 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 75.31 111.147 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 71.55 110.878 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.24 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.42 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.2 tp . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 73.34 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 74.55 110.884 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 74.34 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 73.01 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.44 111.153 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.51 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 72.54 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 72.33 111.111 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.22 110.897 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 64.35 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.2 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.44 111.091 -179.924 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 70.31 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 74.14 110.876 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.33 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 74.4 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.43 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 73.12 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.11 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.24 111.101 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.13 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.45 111.155 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.479 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 75.33 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.22 110.867 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.479 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 73.52 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 63.23 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.408 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.05 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.02 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.111 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.934 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.03 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.31 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 5.3 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 72.34 111.18 -179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 74.13 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 74.3 110.931 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.4 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 75.53 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.406 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.22 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 74.44 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.24 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.03 111.153 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.55 110.885 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 75.55 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 73.42 111.157 -179.985 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.481 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.41 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.54 110.907 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 74.0 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.13 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.409 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 64.05 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 61.42 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.11 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.45 111.091 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 73.34 110.903 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.22 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.11 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.6 tt . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 74.04 111.097 -179.955 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 74.13 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 75.41 110.91 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.23 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.03 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.12 111.127 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.52 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 73.34 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.131 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 73.31 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 74.23 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 75.43 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 71.51 111.102 -179.929 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 73.44 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.1 110.929 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.35 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 74.34 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.44 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 71.23 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 72.53 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.04 111.133 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 74.04 110.94 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 61.31 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.35 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.3 111.084 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 61.45 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 75.03 110.88 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 74.21 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.43 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.403 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.11 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.54 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 75.43 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.42 111.146 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.21 110.935 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 62.14 110.854 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 53.44 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.0 tp . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 73.11 111.157 -179.992 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 75.55 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.44 110.889 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 60.23 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.2 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.41 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 64.52 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 73.14 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.32 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 74.11 111.145 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.13 110.883 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 110.882 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.22 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.6 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 73.21 111.116 -179.993 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.462 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.01 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 71.3 110.923 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.462 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 61.54 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.34 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.404 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 75.42 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 72.13 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 74.04 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 70.44 111.128 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 73.21 110.874 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.41 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 tt . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.45 111.101 -179.93 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.468 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 75.41 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 74.41 110.935 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.468 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.21 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.21 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.41 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.03 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.33 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 71.12 111.122 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 74.53 110.905 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 64.03 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.4 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.31 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 75.22 110.904 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.54 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.24 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.404 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.34 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.13 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 75.04 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.138 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 72.44 110.903 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.841 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 74.44 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.5 tt . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 74.31 111.149 -179.978 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.24 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 73.43 110.905 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.42 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.13 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.401 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 73.35 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 73.33 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.12 111.154 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 75.15 110.906 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 65.12 110.836 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 61.33 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.1 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 74.15 111.148 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.13 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.34 110.926 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 72.22 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 72.54 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 72.0 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.44 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 75.02 111.162 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 73.52 110.938 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.15 110.85 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.41 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.8 tt . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.32 111.154 -179.997 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' PHE . . . . . 0.468 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.32 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.3 110.925 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.468 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 75.11 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.11 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 74.04 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.44 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.103 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 74.44 110.901 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 74.03 110.855 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 71.32 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.4 tp . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 75.13 111.154 -179.992 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.51 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.1 110.899 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 73.43 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 70.23 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.43 111.104 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 72.5 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 73.32 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.21 111.123 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 73.45 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.45 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 70.02 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.1 tp -81.42 -28.97 10.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.12 111.151 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 74.44 110.9 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.41 110.927 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.02 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 74.34 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.4 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.3 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 64.4 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 72.3 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 75.24 111.12 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.13 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 75.34 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 tt -81.49 -28.94 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.22 111.132 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.935 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 75.24 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 73.31 110.95 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.15 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 73.1 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 75.52 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 75.2 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 75.42 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.3 111.146 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 74.53 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 73.22 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 75.2 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.2 tp -84.44 -28.71 6.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 72.44 111.144 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 75.4 110.884 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.31 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 73.43 110.88 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.33 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 73.13 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.407 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.35 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 61.33 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.3 111.142 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 74.51 110.929 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.12 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.3 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -84.46 -28.74 6.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 74.22 111.098 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 75.53 110.938 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.12 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.44 110.943 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.35 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 70.44 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.51 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 74.12 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.1 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 75.31 111.147 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 71.55 110.878 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.24 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.42 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.2 tp -84.5 -28.67 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.8 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.202 -0.453 . . . . 73.41 110.89 179.913 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 73.34 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 74.55 110.884 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 74.34 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 73.01 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.44 111.153 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.51 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 72.54 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 72.33 111.111 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.22 110.897 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 64.35 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.2 tt -88.4 -28.81 5.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.44 111.091 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 72.34 110.9 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 70.31 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 74.14 110.876 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.33 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 74.4 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.43 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 73.12 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.11 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.24 111.101 -179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.13 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.44 -28.73 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.45 111.155 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.7 tp . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 73.42 110.914 179.889 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.479 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 75.33 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.22 110.867 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.479 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 73.52 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 63.23 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.408 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.05 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.02 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.111 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.934 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.03 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.31 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 5.3 tp -84.43 -28.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 72.34 111.18 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 7.4 tt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 74.32 110.892 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 74.13 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 74.3 110.931 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.4 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 75.53 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.406 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.22 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 74.44 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.24 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.03 111.153 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.55 110.885 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 75.55 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 1.2 tt -84.42 -28.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 73.42 111.157 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 22.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 73.42 110.902 179.897 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.481 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.41 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.54 110.907 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.481 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 74.0 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.13 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.409 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 64.05 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 61.42 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.11 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.45 111.091 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 73.34 110.903 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.22 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.11 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.6 tt -84.55 -28.76 6.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 74.04 111.097 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 71.15 110.909 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 74.13 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 75.41 110.91 -179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.23 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.03 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 70.12 111.127 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.52 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 73.34 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.131 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 73.31 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 74.23 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 75.43 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt -81.44 -28.91 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 71.51 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 74.43 110.915 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 73.44 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.1 110.929 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.35 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 74.34 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.44 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 71.23 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 72.53 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.04 111.133 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 74.04 110.94 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 61.31 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.35 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -84.54 -28.67 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.3 111.084 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.214 -0.448 . . . . 74.24 110.913 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 61.45 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 75.03 110.88 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.472 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 74.21 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.43 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.403 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.11 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.54 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 75.43 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.42 111.146 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.21 110.935 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 62.14 110.854 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 53.44 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.0 tp -84.43 -28.73 6.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 73.11 111.157 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.48 . . . . 71.12 110.886 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.476 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 75.55 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.44 110.889 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.476 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 60.23 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.2 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.41 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 64.52 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 73.14 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.32 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 74.11 111.145 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.13 110.883 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 110.882 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.22 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.6 tt -84.51 -28.74 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 73.21 111.116 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.942 179.904 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.462 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.01 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 71.3 110.923 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.462 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 61.54 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.34 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.404 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 75.42 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 72.13 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 74.04 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 70.44 111.128 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 73.21 110.874 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.41 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 tt -84.6 -28.84 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.45 111.101 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 72.43 110.955 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.468 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 75.41 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 74.41 110.935 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.468 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.21 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.21 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.41 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.03 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.33 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 71.12 111.122 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 74.53 110.905 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 75.14 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 64.03 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.4 tt -84.6 -28.75 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 71.41 110.903 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.31 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 75.22 110.904 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.54 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.24 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.404 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.34 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.13 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 75.04 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.138 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 72.44 110.903 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.841 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 74.44 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.5 tt -84.51 -28.79 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 74.31 111.149 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.181 -0.463 . . . . 73.13 110.918 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.24 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 73.43 110.905 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.42 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.13 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.401 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 73.35 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 73.33 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.12 111.154 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 75.15 110.906 179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 65.12 110.836 -179.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 61.33 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.1 tp -84.51 -28.8 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 74.15 111.148 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.492 . . . . 71.35 110.923 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.13 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.34 110.926 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 72.22 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 72.54 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 72.0 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.44 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 75.02 111.162 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 73.52 110.938 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.15 110.85 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.41 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.8 tt -84.53 -28.78 6.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.32 111.154 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 74.33 110.907 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.468 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.32 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.3 110.925 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.468 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 75.11 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.11 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 74.04 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.44 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 73.24 111.103 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 74.44 110.901 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 74.03 110.855 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 71.32 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 2.4 tp -88.1 -28.83 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 75.13 111.154 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 62.45 110.849 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.510000000000005 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.099999999999994 110.899 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 71.540000000000006 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 64.140000000000001 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.648 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.430000000000007 111.104 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 52.130000000000003 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 72.349999999999994 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.099999999999994 111.123 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 71.5 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.450000000000003 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 51.409999999999997 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.1 tp . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.120000000000005 111.151 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.109999999999999 110.927 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.019999999999996 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 70.200000000000003 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.644 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.299999999999997 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 61.310000000000002 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 71.430000000000007 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 73.209999999999994 111.12 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.129999999999995 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 63.539999999999999 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.0 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.219999999999999 111.132 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 64.420000000000002 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 71.420000000000002 110.95 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.150000000000006 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 65.129999999999995 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.209999999999994 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 72.219999999999999 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 71.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.299999999999997 111.146 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 73.430000000000007 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.150000000000006 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 42.229999999999997 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tp . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 64.400000000000006 111.144 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.310000000000002 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 55.240000000000002 110.88 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.329999999999998 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 70.420000000000002 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.638 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.349999999999994 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 52.409999999999997 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.299999999999997 111.142 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 64.530000000000001 110.929 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.120000000000005 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.299999999999997 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 72.5 111.098 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.120000000000005 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.439999999999998 110.943 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.349999999999994 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 60.240000000000002 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.651 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.340000000000003 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.681 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 64.409999999999997 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.099999999999994 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 74.310000000000002 111.147 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.681 HD12 ' O ' ' A' ' 6' ' ' GLY . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 65.200000000000003 110.878 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.239999999999995 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.420000000000002 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.2 tp . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.412 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 62.009999999999998 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.438 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 63.049999999999997 110.884 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 72.200000000000003 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 72.540000000000006 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.652 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.439999999999998 111.153 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.509999999999998 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 64.019999999999996 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.652 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 63.109999999999999 111.111 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.45 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.219999999999999 110.897 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 63.229999999999997 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.2 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.439999999999998 111.091 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 61.420000000000002 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.435 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 73.129999999999995 110.876 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.329999999999998 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 63.0 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.430000000000007 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 62.130000000000003 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.109999999999999 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.239999999999995 111.101 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 73.120000000000005 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.239999999999995 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.129999999999995 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.450000000000003 111.155 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 73.140000000000001 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.219999999999999 110.867 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 62.240000000000002 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 45.119999999999997 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.636 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.340000000000003 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.049999999999997 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.019999999999996 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.636 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 64.310000000000002 111.111 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.403 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.420000000000002 110.934 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.030000000000001 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.310000000000002 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 8' ' ' VAL . 5.3 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 52.43 111.18 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 72.299999999999997 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 73.129999999999995 110.931 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.399999999999999 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 73.420000000000002 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.219999999999999 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 65.420000000000002 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.239999999999995 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.030000000000001 111.153 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.299999999999997 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.549999999999997 110.885 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 65.420000000000002 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 43.219999999999999 111.157 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.409999999999997 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.540000000000006 110.907 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 53.119999999999997 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.129999999999995 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.629 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 63.229999999999997 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 52.520000000000003 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.109999999999999 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.340000000000003 111.091 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 65.310000000000002 110.903 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.109999999999999 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.109999999999999 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.6 tt . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 51.030000000000001 111.097 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 71.030000000000001 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 52.039999999999999 110.91 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.230000000000004 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.030000000000001 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.646 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 34.399999999999999 111.127 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.520000000000003 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 60.009999999999998 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.646 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.340000000000003 111.131 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 72.439999999999998 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 71.209999999999994 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 44.119999999999997 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 64.25 111.102 -179.929 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 71.109999999999999 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.099999999999994 110.929 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.350000000000001 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 64.219999999999999 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.64 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.439999999999998 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 54.109999999999999 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 63.020000000000003 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.64 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.040000000000006 111.133 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 72.239999999999995 110.94 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 53.43 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.350000000000001 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.299999999999997 111.084 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 52.409999999999997 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 73.239999999999995 110.88 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 72.120000000000005 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.430000000000007 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.647 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.109999999999999 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.539999999999999 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 74.319999999999993 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.647 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.420000000000002 111.146 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.507 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.209999999999994 110.935 179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.507 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 60.43 110.854 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 41.32 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.0 tp . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 70.230000000000004 111.157 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 62.140000000000001 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.439999999999998 110.889 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 53.409999999999997 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.200000000000003 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 51.229999999999997 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 71.230000000000004 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.319999999999993 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 51.210000000000001 111.145 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.496 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.129999999999995 110.883 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.496 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.129999999999995 110.882 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.219999999999999 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 8' ' ' VAL . 4.6 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 72.540000000000006 111.116 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.010000000000005 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 70.25 110.923 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 52.439999999999998 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.340000000000003 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.67 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 64.209999999999994 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 52.030000000000001 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 63.43 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.67 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 60.32 111.128 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 72.409999999999997 110.874 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.409999999999997 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 15.9 tt . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.450000000000003 111.101 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 74.409999999999997 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.424 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 73.150000000000006 110.935 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.209999999999994 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.209999999999994 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.659 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.030000000000001 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.411 ' O ' HD23 ' A' ' 9' ' ' LEU . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.329999999999998 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.659 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 63.100000000000001 111.122 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.439 HD12 ' C ' ' A' ' 9' ' ' LEU . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 72.219999999999999 110.905 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 74.420000000000002 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 51.119999999999997 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 8' ' ' VAL . 11.4 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.310000000000002 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 61.240000000000002 110.904 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.540000000000006 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.239999999999995 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.340000000000003 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.130000000000003 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 65.129999999999995 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.209999999999994 111.138 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 71.140000000000001 110.903 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.41 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.239999999999995 110.841 -179.9 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 33.350000000000001 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.5 tt . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 71.439999999999998 111.149 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.413 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 64.200000000000003 110.905 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.420000000000002 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.129999999999995 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 70.319999999999993 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 71.540000000000006 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.120000000000005 111.154 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 62.210000000000001 110.906 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 55.509999999999998 110.836 -179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 53.439999999999998 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.409 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.1 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 73.0 111.148 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.129999999999995 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.340000000000003 110.926 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 64.109999999999999 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 61.039999999999999 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.668 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 71.140000000000001 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 55.130000000000003 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.439999999999998 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 74.319999999999993 111.162 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 54.32 110.938 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.150000000000006 110.85 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.409999999999997 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 8' ' ' VAL . 8.8 tt . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.319999999999993 111.154 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.319999999999993 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.428 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.299999999999997 110.925 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 51.140000000000001 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.109999999999999 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.658 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 60.229999999999997 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.439999999999998 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.439999999999998 111.103 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.530000000000001 110.901 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.415 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 63.520000000000003 110.855 -179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 61.210000000000001 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.431 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.4 tp . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 74.120000000000005 111.154 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.510000000000005 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.099999999999994 110.899 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 71.540000000000006 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 64.140000000000001 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.648 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.430000000000007 111.104 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 52.130000000000003 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 72.349999999999994 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.099999999999994 111.123 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 71.5 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.450000000000003 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 51.409999999999997 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.1 tp -81.42 -28.97 10.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.120000000000005 111.151 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 60.350000000000001 110.9 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.109999999999999 110.927 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.019999999999996 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 70.200000000000003 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.644 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.299999999999997 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 61.310000000000002 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 71.430000000000007 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 73.209999999999994 111.12 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.129999999999995 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 63.539999999999999 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.0 tt -81.49 -28.94 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.219999999999999 111.132 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 61.109999999999999 110.935 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 64.420000000000002 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 71.420000000000002 110.95 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.150000000000006 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 65.129999999999995 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.209999999999994 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 72.219999999999999 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 71.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.299999999999997 111.146 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 73.430000000000007 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.150000000000006 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 42.229999999999997 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tp -84.44 -28.71 6.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 64.400000000000006 111.144 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 75.400000000000006 110.884 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.310000000000002 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 55.240000000000002 110.88 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.329999999999998 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 70.420000000000002 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.638 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.349999999999994 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 52.409999999999997 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.299999999999997 111.142 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 64.530000000000001 110.929 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.120000000000005 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.299999999999997 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER -84.46 -28.74 6.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 72.5 111.098 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 62.32 110.938 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.120000000000005 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.439999999999998 110.943 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.349999999999994 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 60.240000000000002 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.651 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.340000000000003 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.681 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 64.409999999999997 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.099999999999994 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 74.310000000000002 111.147 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.681 HD12 ' O ' ' A' ' 6' ' ' GLY . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 65.200000000000003 110.878 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.239999999999995 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.420000000000002 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.2 tp -84.5 -28.67 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.8 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.202 -0.453 . . . . 64.239999999999995 110.89 179.913 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.412 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 62.009999999999998 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.438 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 63.049999999999997 110.884 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 72.200000000000003 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 72.540000000000006 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.652 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.439999999999998 111.153 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.509999999999998 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 64.019999999999996 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.652 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 63.109999999999999 111.111 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.45 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.219999999999999 110.897 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.409999999999997 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 63.229999999999997 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.2 tt -88.4 -28.81 5.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.439999999999998 111.091 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 63.119999999999997 110.9 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 61.420000000000002 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.435 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 73.129999999999995 110.876 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.329999999999998 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 63.0 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.430000000000007 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 62.130000000000003 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.109999999999999 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.239999999999995 111.101 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 73.120000000000005 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.239999999999995 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.129999999999995 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.5 OUTLIER -89.44 -28.73 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.450000000000003 111.155 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.7 tp . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 73.420000000000002 110.914 179.889 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 73.140000000000001 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.219999999999999 110.867 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 62.240000000000002 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 45.119999999999997 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.636 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.340000000000003 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.049999999999997 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.019999999999996 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.636 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 64.310000000000002 111.111 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.403 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.420000000000002 110.934 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.030000000000001 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.310000000000002 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 8' ' ' VAL . 5.3 tp -84.43 -28.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 52.43 111.18 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 7.4 tt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 74.319999999999993 110.892 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 72.299999999999997 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 73.129999999999995 110.931 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.399999999999999 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 73.420000000000002 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.219999999999999 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 65.420000000000002 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.239999999999995 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.030000000000001 111.153 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.299999999999997 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.533 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.549999999999997 110.885 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 65.420000000000002 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tt -84.42 -28.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 43.219999999999999 111.157 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.533 HD12 ' HA ' ' A' ' 10' ' ' SER . 22.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 53.350000000000001 110.902 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.409999999999997 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.540000000000006 110.907 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 53.119999999999997 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.129999999999995 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.629 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 63.229999999999997 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 52.520000000000003 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.109999999999999 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.340000000000003 111.091 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 65.310000000000002 110.903 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.109999999999999 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.109999999999999 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.6 tt -84.55 -28.76 6.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 51.030000000000001 111.097 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 71.150000000000006 110.909 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 71.030000000000001 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 52.039999999999999 110.91 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.230000000000004 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.030000000000001 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.646 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 34.399999999999999 111.127 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.520000000000003 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 60.009999999999998 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.646 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.340000000000003 111.131 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 72.439999999999998 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 71.209999999999994 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 44.119999999999997 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt -81.44 -28.91 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 64.25 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 74.430000000000007 110.915 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 71.109999999999999 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.099999999999994 110.929 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.350000000000001 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 64.219999999999999 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.64 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.439999999999998 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 54.109999999999999 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 63.020000000000003 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.64 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.040000000000006 111.133 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 72.239999999999995 110.94 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 53.43 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.350000000000001 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.9 OUTLIER -84.54 -28.67 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.299999999999997 111.084 -179.944 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.214 -0.448 . . . . 55.210000000000001 110.913 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 52.409999999999997 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 73.239999999999995 110.88 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 72.120000000000005 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.430000000000007 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.647 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.109999999999999 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.539999999999999 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 74.319999999999993 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.647 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.420000000000002 111.146 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.507 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.209999999999994 110.935 179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.507 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 60.43 110.854 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 41.32 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.0 tp -84.43 -28.73 6.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 70.230000000000004 111.157 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.48 . . . . 70.540000000000006 110.886 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 62.140000000000001 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.439999999999998 110.889 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 53.409999999999997 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.200000000000003 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 51.229999999999997 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 71.230000000000004 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.319999999999993 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 51.210000000000001 111.145 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.496 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.129999999999995 110.883 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.496 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.129999999999995 110.882 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.219999999999999 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 8' ' ' VAL . 4.6 tt -84.51 -28.74 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 72.540000000000006 111.116 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 71.409999999999997 110.942 179.904 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.010000000000005 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 70.25 110.923 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 52.439999999999998 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.340000000000003 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.67 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 64.209999999999994 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 52.030000000000001 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 63.43 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.67 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 60.32 111.128 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 72.409999999999997 110.874 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.409999999999997 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 15.9 tt -84.6 -28.84 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.450000000000003 111.101 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 72.430000000000007 110.955 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 74.409999999999997 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.424 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 73.150000000000006 110.935 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.209999999999994 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.209999999999994 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.659 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.030000000000001 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.411 ' O ' HD23 ' A' ' 9' ' ' LEU . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.329999999999998 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.659 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 63.100000000000001 111.122 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.439 HD12 ' C ' ' A' ' 9' ' ' LEU . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 72.219999999999999 110.905 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 74.420000000000002 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 51.119999999999997 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 8' ' ' VAL . 11.4 tt -84.6 -28.75 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 70.549999999999997 110.903 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.310000000000002 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 61.240000000000002 110.904 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.540000000000006 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.239999999999995 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.340000000000003 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.130000000000003 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 65.129999999999995 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.209999999999994 111.138 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 71.140000000000001 110.903 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.41 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.239999999999995 110.841 -179.9 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 33.350000000000001 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.5 tt -84.51 -28.79 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 71.439999999999998 111.149 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.181 -0.463 . . . . 73.129999999999995 110.918 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.413 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.239999999999995 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 64.200000000000003 110.905 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.420000000000002 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.129999999999995 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 70.319999999999993 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 71.540000000000006 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.120000000000005 111.154 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 62.210000000000001 110.906 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 55.509999999999998 110.836 -179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 53.439999999999998 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.409 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.1 tp -84.51 -28.8 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 73.0 111.148 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.492 . . . . 60.020000000000003 110.923 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.129999999999995 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.340000000000003 110.926 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 64.109999999999999 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 61.039999999999999 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.668 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 71.140000000000001 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 55.130000000000003 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.439999999999998 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 74.319999999999993 111.162 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 54.32 110.938 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.150000000000006 110.85 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.409999999999997 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 8' ' ' VAL . 8.8 tt -84.53 -28.78 6.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.319999999999993 111.154 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 74.329999999999998 110.907 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.319999999999993 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.428 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.299999999999997 110.925 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 51.140000000000001 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.109999999999999 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.658 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 60.229999999999997 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.439999999999998 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.439999999999998 111.103 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.530000000000001 110.901 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.415 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 63.520000000000003 110.855 -179.933 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 61.210000000000001 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.431 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.4 tp -88.1 -28.83 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 74.120000000000005 111.154 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 62.450000000000003 110.849 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.51 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.1 110.899 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 71.54 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 64.14 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.648 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.43 111.104 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 52.13 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 72.35 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.1 111.123 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 71.5 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.45 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 51.41 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.1 tp . . . . . 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.12 111.151 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.11 110.927 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.02 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 70.2 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.644 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.3 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 61.31 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 71.43 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 73.21 111.12 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.13 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 63.54 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.0 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.22 111.132 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 64.42 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 71.42 110.95 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.15 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 65.13 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.21 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 72.22 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 71.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.3 111.146 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 73.43 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.15 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 42.23 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tp . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 64.4 111.144 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.31 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 55.24 110.88 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.33 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 70.42 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.638 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.35 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 52.41 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.3 111.142 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 64.53 110.929 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.12 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.3 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 72.5 111.098 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.12 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.44 110.943 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.35 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 60.24 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.651 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.34 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.681 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 64.41 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.1 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 74.31 111.147 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.681 HD12 ' O ' ' A' ' 6' ' ' GLY . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 65.2 110.878 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.24 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.42 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.2 tp . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.412 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 62.01 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.438 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 63.05 110.884 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 72.2 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 72.54 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.652 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.44 111.153 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.51 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 64.02 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.652 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 63.11 111.111 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.45 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.22 110.897 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 63.23 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.2 tt . . . . . 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.44 111.091 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 61.42 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.435 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 73.13 110.876 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.33 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 63.0 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.43 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 62.13 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.11 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.24 111.101 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 73.12 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.13 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.45 111.155 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 73.14 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.22 110.867 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 62.24 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 45.12 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.636 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.05 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.02 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.636 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 64.31 111.111 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.403 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.934 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.03 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.31 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 8' ' ' VAL . 5.3 tp . . . . . 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 52.43 111.18 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 72.3 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 73.13 110.931 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.4 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 73.42 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.22 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 65.42 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.24 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.03 111.153 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.55 110.885 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 65.42 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 43.22 111.157 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.41 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.54 110.907 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 53.12 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.13 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.629 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 52.52 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.11 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.34 111.091 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 65.31 110.903 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.11 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.11 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.6 tt . . . . . 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 51.03 111.097 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 71.03 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 52.04 110.91 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.23 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.03 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.646 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 34.4 111.127 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.52 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 60.01 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.646 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.131 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 71.21 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 44.12 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt . . . . . 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 64.25 111.102 -179.929 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 71.11 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.1 110.929 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.35 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.64 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.44 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 54.11 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 63.02 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.64 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.04 111.133 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.94 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 53.43 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.35 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.3 111.084 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 52.41 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 73.24 110.88 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 72.12 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.43 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.647 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.11 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.54 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 74.32 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.647 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.42 111.146 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.507 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.21 110.935 179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.507 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 60.43 110.854 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 41.32 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.0 tp . . . . . 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 70.23 111.157 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 62.14 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.44 110.889 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 53.41 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.2 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 51.23 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 71.23 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.32 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 51.21 111.145 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.496 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.13 110.883 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.496 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 110.882 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.22 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 8' ' ' VAL . 4.6 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 72.54 111.116 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.01 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 70.25 110.923 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 52.44 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.34 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.67 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 64.21 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 52.03 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 63.43 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.67 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 60.32 111.128 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 72.41 110.874 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.41 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 15.9 tt . . . . . 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.45 111.101 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 74.41 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.424 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 73.15 110.935 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.21 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.21 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.659 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.03 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.411 ' O ' HD23 ' A' ' 9' ' ' LEU . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.33 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.659 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 63.1 111.122 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.439 HD12 ' C ' ' A' ' 9' ' ' LEU . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 72.22 110.905 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 51.12 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 8' ' ' VAL . 11.4 tt . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.31 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 61.24 110.904 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.54 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.24 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.34 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.13 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 65.13 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.138 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 71.14 110.903 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.41 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.841 -179.9 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 33.35 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.5 tt . . . . . 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 71.44 111.149 -179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.413 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.24 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 64.2 110.905 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.42 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.13 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 70.32 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 71.54 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.12 111.154 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 62.21 110.906 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 55.51 110.836 -179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 53.44 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.409 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.1 tp . . . . . 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 73.0 111.148 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.13 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.34 110.926 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 64.11 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 61.04 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.668 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 71.14 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 55.13 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.44 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 74.32 111.162 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 54.32 110.938 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.15 110.85 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.41 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 8' ' ' VAL . 8.8 tt . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.32 111.154 -179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.32 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.428 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.3 110.925 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 51.14 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.11 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.658 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 60.23 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.44 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.44 111.103 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.53 110.901 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.415 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 63.52 110.855 -179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 61.21 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.431 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.4 tp . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 74.12 111.154 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.845 0.355 . . . . 74.51 110.925 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.9 113.91 56.84 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.645 0.736 . . . . 74.1 110.899 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.72 0.33 5.78 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.739 2.293 . . . . 71.54 112.336 179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.1 mt -93.15 -25.23 17.95 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.229 -0.441 . . . . 64.14 110.946 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.648 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.11 -37.23 76.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.173 -0.467 . . . . 75.43 111.104 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.71 -13.08 80.58 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.734 -0.746 . . . . 52.13 112.47 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.16 10.58 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.856 0.36 . . . . 72.35 110.874 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.648 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.8 p -46.63 -30.82 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.177 -0.465 . . . . 74.1 111.123 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.78 -43.08 65.6 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 71.5 110.909 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.5 t -103.01 -29.89 11.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.47 . . . . 74.45 110.854 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.37 -25.2 72.48 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.792 -0.718 . . . . 51.41 112.469 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.1 tp -81.42 -28.97 10.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.855 0.359 . . . . 75.12 111.151 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.162 -0.472 . . . . 60.35 110.9 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.16 0 CA-C-O 120.868 0.366 . . . . 73.5 110.903 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.3 OUTLIER -109.85 113.86 57.0 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.565 0.698 . . . . 74.11 110.927 -179.968 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.77 0.41 5.69 Favored 'Trans proline' 0 C--O 1.233 0.228 0 C-N-CA 122.743 2.295 . . . . 74.02 112.321 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.9 mt -93.27 -25.14 17.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 70.2 110.889 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.644 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.24 76.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 74.3 111.109 179.821 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.4 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.75 -13.04 80.61 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.742 -0.742 . . . . 61.31 112.488 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.19 10.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.835 0.35 . . . . 71.43 110.834 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.644 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.85 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 73.21 111.12 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -52.81 -43.0 65.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 72.13 110.918 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 2.0 t -103.01 -29.95 11.07 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.455 . . . . 74.25 110.825 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.29 -25.27 72.38 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.777 -0.725 . . . . 63.54 112.491 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.401 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.0 tt -81.49 -28.94 10.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.849 0.357 . . . . 74.22 111.132 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 61.11 110.935 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.89 0.376 . . . . 64.42 110.886 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.83 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.647 0.737 . . . . 71.42 110.95 179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.41 5.7 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.647 2.231 . . . . 64.15 112.34 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.4 mt -93.16 -25.21 17.95 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.197 -0.456 . . . . 65.13 110.94 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.23 76.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 72.21 111.093 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.69 -13.09 80.62 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.763 -0.732 . . . . 72.22 112.489 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.19 10.58 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.837 0.351 . . . . 71.0 110.887 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.67 -30.73 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 74.3 111.146 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 mp -52.89 -43.05 65.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.146 -0.479 . . . . 73.43 110.894 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -102.99 -29.83 11.16 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.23 -0.441 . . . . 70.15 110.876 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.08 -23.81 71.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.789 -0.719 . . . . 42.23 112.452 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tp -84.44 -28.71 6.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 64.4 111.144 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.178 -0.464 . . . . 75.4 110.884 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.424 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.881 0.372 . . . . 73.31 110.889 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.2 mp -109.88 113.91 56.89 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.61 0.719 . . . . 55.24 110.88 180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.424 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.39 5.73 Favored 'Trans proline' 0 C--O 1.232 0.205 0 C-N-CA 122.672 2.248 . . . . 73.33 112.344 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.2 mt -93.19 -25.18 17.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.45 . . . . 70.42 110.907 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.638 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.1 -37.28 76.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.219 -0.446 . . . . 74.35 111.147 179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.407 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.68 -13.04 80.72 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.725 -0.75 . . . . 52.41 112.53 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.18 10.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.844 0.354 . . . . 74.25 110.899 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.638 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.6 p -46.57 -30.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 74.3 111.142 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.427 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.3 OUTLIER -52.83 -43.03 65.7 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 64.53 110.929 179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.99 -29.84 11.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.449 . . . . 73.12 110.878 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.15 -23.73 71.55 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.714 -0.755 . . . . 70.3 112.453 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.7 OUTLIER -84.46 -28.74 6.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.859 0.362 . . . . 72.5 111.098 -179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.169 -0.468 . . . . 62.32 110.938 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.922 0.391 . . . . 74.12 110.894 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.4 mp -109.9 113.93 56.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.616 0.722 . . . . 75.44 110.943 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.77 0.39 5.72 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.686 2.257 . . . . 71.35 112.345 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.23 -25.14 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 60.24 110.9 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.651 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.16 -37.2 76.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 71.34 111.1 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.681 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -81.85 -12.83 80.77 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.715 -0.755 . . . . 64.41 112.497 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.28 -33.07 10.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.856 0.36 . . . . 71.1 110.892 -179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.651 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.5 p -46.34 -31.29 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.194 -0.457 . . . . 74.31 111.147 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.681 HD12 ' O ' ' A' ' 6' ' ' GLY . 1.7 mt -52.34 -43.37 64.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 65.2 110.878 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -102.79 -29.84 11.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 74.24 110.864 -179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.1 -23.81 71.52 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.739 -0.743 . . . . 50.42 112.462 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.2 tp -84.5 -28.67 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.35 . . . . 73.25 111.112 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 5.8 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.202 -0.453 . . . . 64.24 110.89 179.913 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.412 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.9 0.381 . . . . 62.01 110.87 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.438 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.4 mm? -109.93 113.92 56.78 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.616 0.722 . . . . 63.05 110.884 -179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.412 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.78 0.43 5.68 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.654 2.236 . . . . 72.2 112.34 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.5 mt -93.19 -25.2 17.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 72.54 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.652 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.22 -37.12 75.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.184 -0.462 . . . . 71.44 111.153 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.79 -13.08 80.45 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.768 -0.729 . . . . 60.51 112.51 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.04 -33.24 10.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.87 0.367 . . . . 64.02 110.874 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.652 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.56 -30.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.209 -0.451 . . . . 63.11 111.111 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.45 HD13 ' O ' ' A' ' 9' ' ' LEU . 0.4 OUTLIER -52.69 -43.13 65.38 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 75.22 110.897 179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.95 -29.91 11.12 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.875 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.58 -22.17 69.53 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.756 -0.735 . . . . 63.23 112.475 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.2 tt -88.4 -28.81 5.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.88 0.372 . . . . 64.44 111.091 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 63.12 110.9 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.9 0.381 . . . . 61.42 110.893 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.435 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.4 mt -109.89 113.98 56.8 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.648 0.737 . . . . 73.13 110.876 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.1 Cg_endo -69.74 0.4 5.69 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.716 2.277 . . . . 70.33 112.337 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.3 mt -93.26 -25.2 17.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.265 -0.425 . . . . 63.0 110.905 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.18 -37.18 75.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 74.43 111.127 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.71 -13.06 80.62 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.749 -0.739 . . . . 62.13 112.453 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.08 -33.23 10.56 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.824 0.345 . . . . 75.11 110.817 -179.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.7 p -46.58 -30.88 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 64.24 111.101 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 mp -52.78 -43.03 65.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.172 -0.467 . . . . 73.12 110.921 179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.96 -29.83 11.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 64.24 110.914 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.65 -21.57 69.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.747 -0.739 . . . . 75.13 112.484 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.437 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.5 OUTLIER -89.44 -28.73 5.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-O 120.875 0.369 . . . . 74.45 111.155 -179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.7 tp . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 73.42 110.914 179.889 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.149 0 CA-C-O 120.883 0.373 . . . . 73.14 110.905 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.96 114.03 56.6 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.618 0.723 . . . . 74.22 110.867 -179.961 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.85 0.46 5.68 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.704 2.27 . . . . 62.24 112.298 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.29 -25.14 17.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 45.12 110.941 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.636 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.19 -37.21 75.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.139 179.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.58 -13.12 80.74 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.79 -0.719 . . . . 74.05 112.444 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.09 -33.16 10.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.856 0.36 . . . . 75.02 110.874 -179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.636 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.86 -30.07 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.201 -0.454 . . . . 64.31 111.111 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.403 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.6 -43.07 68.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 73.42 110.934 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.94 -29.83 11.18 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.151 -0.477 . . . . 63.03 110.857 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.0 -23.76 71.32 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 72.31 112.483 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.403 HG22 ' O ' ' A' ' 8' ' ' VAL . 5.3 tp -84.43 -28.69 6.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.896 0.379 . . . . 52.43 111.18 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 7.4 tt . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 74.32 110.892 179.895 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.911 0.386 . . . . 72.3 110.899 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.437 ' HB3' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -109.9 113.86 56.89 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.634 0.731 . . . . 73.13 110.931 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.73 0.37 5.72 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.694 2.262 . . . . 54.4 112.343 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.1 mt -93.17 -25.21 17.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 73.42 110.914 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.643 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.15 -37.3 76.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.193 -0.458 . . . . 75.22 111.133 179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.752 -0.737 . . . . 65.42 112.512 179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.03 -33.15 10.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.872 0.368 . . . . 73.24 110.893 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.643 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.81 -30.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 72.03 111.153 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.6 -43.06 68.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 72.3 110.933 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.533 ' HA ' HD12 ' A' ' 13' ' ' LEU . 1.6 t -102.92 -29.85 11.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.182 -0.463 . . . . 74.55 110.885 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.96 -23.78 71.27 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.757 -0.735 . . . . 65.42 112.504 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 1.2 tt -84.42 -28.75 6.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.918 0.389 . . . . 43.22 111.157 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.533 HD12 ' HA ' ' A' ' 10' ' ' SER . 22.9 mt . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 53.35 110.902 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.425 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.899 0.381 . . . . 73.41 110.914 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 1.7 mt -109.74 113.7 57.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.61 0.719 . . . . 72.54 110.907 -179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.425 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.5 Cg_endo -69.82 0.31 5.87 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.652 2.234 . . . . 53.12 112.306 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 57.6 mt -92.96 -25.14 18.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.433 . . . . 73.13 110.944 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.629 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.4 -37.52 75.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 63.23 111.123 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.409 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.77 -13.14 80.36 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.738 -0.744 . . . . 52.52 112.48 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.15 10.62 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.846 0.355 . . . . 65.11 110.92 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.629 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.4 p -46.98 -30.16 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 74.34 111.091 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.412 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.58 -42.91 68.08 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.238 -0.437 . . . . 65.31 110.903 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.2 t -102.91 -29.78 11.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.138 -0.483 . . . . 74.11 110.842 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.06 -23.83 71.45 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.748 -0.739 . . . . 73.11 112.502 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.412 HG22 ' O ' ' A' ' 8' ' ' VAL . 3.6 tt -84.55 -28.76 6.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.837 0.351 . . . . 51.03 111.097 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.16 -0.473 . . . . 71.15 110.909 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.421 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.901 0.381 . . . . 71.03 110.878 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.443 ' HB3' HG23 ' A' ' 5' ' ' ILE . 7.1 mp -109.9 113.89 56.87 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.567 0.699 . . . . 52.04 110.91 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.421 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.7 Cg_endo -69.76 0.43 5.66 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.657 2.238 . . . . 72.23 112.37 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.6 mt -93.24 -25.21 17.89 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.18 -0.463 . . . . 74.03 110.891 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.646 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.09 -37.28 76.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.201 -0.454 . . . . 34.4 111.127 179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -81.52 -13.2 80.68 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.719 -0.753 . . . . 50.52 112.472 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.0 -33.14 10.62 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.838 0.351 . . . . 60.01 110.85 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.646 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -29.95 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.193 -0.458 . . . . 73.34 111.131 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -53.75 -43.05 68.82 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.195 -0.457 . . . . 72.44 110.926 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 72.1 m -102.88 -29.87 11.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 71.21 110.887 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.25 -25.21 72.32 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 44.12 112.521 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 tt -81.44 -28.91 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.809 0.338 . . . . 64.25 111.102 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.194 -0.457 . . . . 74.43 110.915 179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.423 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.848 0.356 . . . . 71.11 110.897 . . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.7 OUTLIER -109.86 113.86 56.97 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.58 0.705 . . . . 70.1 110.929 179.997 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.423 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.75 0.43 5.65 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.657 2.238 . . . . 63.35 112.345 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.6 mt -93.22 -25.22 17.9 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 64.22 110.908 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.64 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.14 -37.22 76.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 74.44 111.161 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.56 -13.2 80.62 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.704 -0.76 . . . . 54.11 112.464 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.01 -33.08 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.858 0.361 . . . . 63.02 110.883 -179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.64 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.92 -30.04 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.197 -0.456 . . . . 74.04 111.133 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.401 HD13 ' HA ' ' A' ' 9' ' ' LEU . 4.1 mm? -53.64 -42.97 68.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.143 -0.48 . . . . 72.24 110.94 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -102.96 -29.89 11.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.214 -0.448 . . . . 53.43 110.857 -179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.01 -23.67 71.29 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.716 -0.754 . . . . 55.35 112.501 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 0.9 OUTLIER -84.54 -28.67 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.836 0.35 . . . . 75.3 111.084 -179.944 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.214 -0.448 . . . . 55.21 110.913 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.419 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.904 0.383 . . . . 52.41 110.862 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.439 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.91 113.89 56.85 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.634 0.731 . . . . 73.24 110.88 -179.989 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.419 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 54.4 Cg_endo -69.71 0.4 5.66 Favored 'Trans proline' 0 C--O 1.232 0.182 0 C-N-CA 122.706 2.271 . . . . 72.12 112.383 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.26 -25.19 17.89 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.466 . . . . 74.43 110.878 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.647 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.17 -37.18 76.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.212 -0.449 . . . . 75.11 111.153 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.6 -13.12 80.7 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.716 -0.754 . . . . 43.54 112.505 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.05 -33.17 10.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.87 0.367 . . . . 74.32 110.862 -179.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.647 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.1 p -46.95 -29.99 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.231 -0.44 . . . . 72.42 111.146 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.507 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -53.88 -42.73 68.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.462 . . . . 71.21 110.935 179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.507 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.2 OUTLIER -103.03 -29.87 11.12 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 60.43 110.854 -179.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.11 -23.71 71.48 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.757 -0.735 . . . . 41.32 112.494 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.406 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.0 tp -84.43 -28.73 6.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.898 0.38 . . . . 70.23 111.157 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 1.2 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.48 . . . . 70.54 110.886 179.952 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.422 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.881 0.372 . . . . 62.14 110.848 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.43 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.8 113.64 57.31 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.593 0.711 . . . . 73.44 110.889 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.422 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.35 5.76 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.706 2.271 . . . . 53.41 112.35 179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.9 mt -93.01 -25.23 18.06 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 73.2 110.882 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.642 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -69.38 -37.47 75.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 51.23 111.124 179.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.41 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.76 -13.14 80.38 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.74 -0.743 . . . . 71.23 112.466 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.1 -33.09 10.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.828 0.347 . . . . 73.32 110.856 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.642 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.3 p -47.15 -29.92 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.21 -0.45 . . . . 51.21 111.145 179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.496 HD23 ' N ' ' A' ' 10' ' ' SER . 0.4 OUTLIER -54.02 -42.59 69.31 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 73.13 110.883 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.496 ' N ' HD23 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -102.88 -29.89 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 110.882 -179.95 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.18 -23.75 71.61 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.713 -0.756 . . . . 71.22 112.514 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.408 HG22 ' O ' ' A' ' 8' ' ' VAL . 4.6 tt -84.51 -28.74 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.87 0.367 . . . . 72.54 111.116 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 71.41 110.942 179.904 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.886 0.374 . . . . 74.01 110.901 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 4.9 mp -109.96 114.03 56.59 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.622 0.725 . . . . 70.25 110.923 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.52 5.5 Favored 'Trans proline' 0 C--O 1.232 0.203 0 C-N-CA 122.694 2.263 . . . . 52.44 112.328 179.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 55.8 mt -93.52 -25.17 17.7 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.229 -0.442 . . . . 74.34 110.903 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.67 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.93 -37.5 77.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.231 -0.441 . . . . 64.21 111.137 179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.01 -11.94 81.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.706 -0.759 . . . . 52.03 112.46 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.18 -31.27 11.11 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.81 0.338 . . . . 63.43 110.886 -179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.67 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.37 -31.01 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.18 -0.464 . . . . 60.32 111.128 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.17 -39.84 69.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.196 -0.456 . . . . 72.41 110.874 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 1.6 t -103.19 -30.1 10.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.236 -0.438 . . . . 61.25 110.865 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.74 -23.35 74.0 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.776 -0.726 . . . . 70.41 112.445 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.41 HG22 ' O ' ' A' ' 8' ' ' VAL . 15.9 tt -84.6 -28.84 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.892 0.377 . . . . 72.45 111.101 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 72.43 110.955 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.42 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.89 0.376 . . . . 74.41 110.889 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.424 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.6 mm? -110.02 114.06 56.44 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.625 0.726 . . . . 73.15 110.935 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.3 Cg_endo -69.77 0.53 5.51 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.652 2.234 . . . . 71.21 112.323 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 53.1 mt -93.45 -25.27 17.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.242 -0.436 . . . . 74.21 110.898 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.659 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.91 -37.59 77.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.448 . . . . 74.03 111.101 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.411 ' O ' HD23 ' A' ' 9' ' ' LEU . . . -81.85 -12.18 81.69 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.725 -0.75 . . . . 75.33 112.502 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -100.96 -31.47 11.11 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.918 0.389 . . . . 74.5 110.9 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.659 HG12 ' O ' ' A' ' 5' ' ' ILE . 10.5 p -47.77 -30.34 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 63.1 111.122 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.439 HD12 ' C ' ' A' ' 9' ' ' LEU . 2.6 pp -56.33 -39.23 72.46 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.218 -0.446 . . . . 72.22 110.905 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -103.22 -30.0 10.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.188 -0.46 . . . . 74.42 110.838 -179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.01 -23.29 74.44 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.714 -0.755 . . . . 51.12 112.514 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.404 HG22 ' O ' ' A' ' 8' ' ' VAL . 11.4 tt -84.6 -28.75 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.8 0.334 . . . . 62.43 111.128 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.21 -0.45 . . . . 70.55 110.903 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.415 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.903 0.382 . . . . 75.31 110.895 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -109.94 114.05 56.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.606 0.717 . . . . 61.24 110.904 -179.966 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.415 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.6 Cg_endo -69.78 0.55 5.49 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.636 2.224 . . . . 75.54 112.377 179.838 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.2 mt -93.42 -25.18 17.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 74.24 110.976 179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.92 -37.51 77.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.115 -0.493 . . . . 74.34 111.108 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.98 -11.99 81.77 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.761 -0.733 . . . . 63.13 112.515 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.14 -31.34 11.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.884 0.373 . . . . 65.13 110.907 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.36 -30.96 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.138 -0.483 . . . . 74.21 111.138 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.451 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.18 -39.82 69.99 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.163 -0.472 . . . . 71.14 110.903 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.41 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.24 -30.01 10.92 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.841 -179.9 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.76 -23.44 74.05 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.76 -0.733 . . . . 33.35 112.505 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 8' ' ' VAL . 16.5 tt -84.51 -28.79 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.866 0.365 . . . . 71.44 111.149 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.181 -0.463 . . . . 73.13 110.918 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.413 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.913 0.387 . . . . 74.24 110.887 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.8 mp -109.97 114.0 56.61 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.623 0.725 . . . . 64.2 110.905 -179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.413 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.8 Cg_endo -69.73 0.46 5.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.73 2.287 . . . . 73.42 112.322 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 52.3 mt -93.4 -25.24 17.76 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.254 -0.43 . . . . 74.13 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.671 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.95 -37.45 77.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 70.32 111.111 179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.99 -12.02 81.71 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.771 -0.728 . . . . 73.0 112.5 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.13 -31.32 11.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.836 0.351 . . . . 71.54 110.882 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.671 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.2 p -47.24 -31.09 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 75.12 111.154 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.13 -39.82 69.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.125 -0.489 . . . . 62.21 110.906 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.5 OUTLIER -103.22 -30.21 10.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.227 -0.442 . . . . 55.51 110.836 -179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -23.4 73.72 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.686 -0.769 . . . . 53.44 112.511 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.409 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.1 tp -84.51 -28.8 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-O 120.891 0.377 . . . . 73.0 111.148 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.492 . . . . 60.02 110.923 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.416 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.919 0.39 . . . . 74.13 110.843 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.432 ' HB3' HG23 ' A' ' 5' ' ' ILE . 3.5 mm? -109.97 114.08 56.52 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.603 0.716 . . . . 71.34 110.926 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.9 Cg_endo -69.8 0.58 5.48 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.675 2.25 . . . . 64.11 112.321 179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.7 mt -93.5 -25.15 17.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.226 -0.443 . . . . 61.04 110.949 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.668 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.7 pt -68.94 -37.5 77.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 71.14 111.125 179.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -81.94 -12.06 81.73 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.767 -0.73 . . . . 55.13 112.465 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.11 -31.29 11.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.862 0.363 . . . . 73.44 110.886 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.1 p -47.37 -30.92 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 74.32 111.162 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.452 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.21 -39.78 70.05 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.219 -0.446 . . . . 54.32 110.938 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.412 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.22 -30.13 10.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.19 -0.459 . . . . 73.15 110.85 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.71 -23.38 73.96 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.692 -0.766 . . . . 74.41 112.531 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 8' ' ' VAL . 8.8 tt -84.53 -28.78 6.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 73.32 111.154 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 74.33 110.907 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.418 ' CZ ' ' HA ' ' A' ' 3' ' ' PRO . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.863 0.363 . . . . 75.32 110.869 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.428 ' HB3' HG23 ' A' ' 5' ' ' ILE . 6.1 mt -110.02 114.05 56.45 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 121.626 0.727 . . . . 73.3 110.925 -179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.418 ' HA ' ' CZ ' ' A' ' 1' ' ' PHE . 53.4 Cg_endo -69.74 0.57 5.44 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.66 2.24 . . . . 51.14 112.373 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.0 mt -93.46 -25.28 17.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 65.11 110.894 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.658 ' O ' HG12 ' A' ' 8' ' ' VAL . 1.6 pt -68.82 -37.49 77.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 60.23 111.162 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.405 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . -82.04 -11.98 81.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.79 -0.719 . . . . 43.32 112.501 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.16 -31.36 11.07 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.851 0.357 . . . . 74.44 110.854 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 5' ' ' ILE . 11.3 p -47.26 -31.17 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.44 111.103 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 9' ' ' LEU . 3.0 pp -55.08 -39.84 69.73 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.172 -0.467 . . . . 71.53 110.901 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.415 ' N ' HD12 ' A' ' 9' ' ' LEU . 0.3 OUTLIER -103.21 -29.94 10.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.178 -0.464 . . . . 63.52 110.855 -179.933 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.49 -21.84 72.79 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.713 -0.756 . . . . 61.21 112.479 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.431 HG22 ' O ' ' A' ' 8' ' ' VAL . 2.4 tp -88.1 -28.83 5.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.874 0.368 . . . . 74.12 111.154 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 62.45 110.849 179.909 . . . . . . . . 1 1 . 1 stop_ save_